weight loss drug

2025.01.24

22:31

U.S. stocks opened, with the Dow Jones Industrial Average down 0.07%, the S&P 500 Index up 0.03%, and the Nasdaq Composite Index up 0.15%. Novo Nordisk (NVO.N) rose 10.62% after clinical trials showed that its weight loss drug Amycretin can reduce weight by 22%. Meta Platforms (META.O) fell 0.19%, CEO Zuckerberg plans to significantly expand the artificial intelligence team. Nvidia (NVDA.O) rose 1%.

18:41

Novo Nordisk (NVO.N) shares rose more than 8% in pre-market trading in the U.S. as clinical trials showed its weight loss drug Amycretin reduced body weight by 22%.

18:38

Novo Nordisk's US stock rose more than 8% before the market opened. Clinical trials showed that its weight loss drug Amycretin reduced body weight by 22%.

Novo Nordisk's US stock rose more than 8% in pre-market trading. The company announced the results of a Phase 1b/2a clinical trial for Amycretin. Patients treated with Amycretin lost 9.7% of their body weight after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks. Based on this result, Novo Nordisk is planning to further develop Amycretin for overweight or obese adults.

2025.01.17

21:03

Novo Nordisk's weight loss drugs Ozempic and Wegovy are in the spotlight in Medicare price negotiations.

2025.01.14

22:35

Eli Lilly (LLY.N) fell 2.6 percent as it forecast weak fourth-quarter sales of its diet pills.

2025.01.13

23:47

Eli Lilly (LLY.N) CEO: New weight loss drug is expected to be approved in early 2026.

23:47

Eli Lilly CEO: New weight loss drug expected to be approved in early 2026

Eli Lilly's CEO said the new weight loss drug is expected to be approved in early 2026.

2025.01.06

09:27

At the opening of A-shares, the Shanghai Composite Index fell 0.05%, the Shenzhen Component Index fell 0.06%, and the ChiNext Index rose 0.11%. Flu, diet pills, and vitamin concept stocks led the gains.

2024.12.25

16:12

Lilly's weight loss drug sold on Chinese e-commerce platforms

A number of e-commerce platforms in China have already provided treatment pickup services for Eli Lilly's glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide (trade name: Mounjaro).

2024.12.23

22:33

Novo Nordisk rebounded by more than 4%

Novo Nordisk rebounded more than 4%, as analysts said the company's weight loss drugs are still the most effective.

2024.12.21

05:37

Eli Lilly's weight-loss drug Zepbound approved for sleep apnea

Eli Lilly's weight loss drug Zepbound has been approved to treat sleep apnea.

2024.12.20

22:33

Eli Lilly (LLY.N) rose more than 4% as rival Novo Nordisk's weight loss drug trial results fell short of expectations.

19:12

Novo Nordisk's pre-market decline in US stocks narrowed to 20%, while Eli Lilly rose more than 10%

Novo Nordisk's pre-market decline narrowed to 20%, after a sharp drop of nearly 30%, the largest single-day drop on record, due to the company's weight loss drug CagriSema trial results falling short of expectations. Eli Lilly's pre-market rise was more than 10%.

19:04

Novo Nordisk shares plunge 27%, dragging down Stoxx Europe 600 2%

The Stoxx Europe 600 index fell 2% to 496.52 points. Novo Nordisk shares plunged 27%, the biggest one-day drop in 22 years, as the results of the Novo Nordisk weight loss drug CagriSema trial fell short of expectations. Novo Nordisk said on Friday that its experimental next-generation obesity drug CagriSema helped overweight patients lose 22.7% of their weight in a late-stage trial, lower than its expected 25%, causing its shares to fall sharply.

19:01

Novo Nordisk shares plunged 23%, their biggest one-day drop in 22 years, after the company's weight-loss drug CagriSema trial results fell short of expectations.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03